Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone HCl) Nasal Spray as the first FDA-approved ...
Business Wire
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and ...
Edema and fluid overload remain the leading causes of hospitalization and readmission for patients with CHF, cirrhosis, and chronic kidney disease. An estimated 6.7 million Americans live with heart ...
Becker's Hospital Review
‘It’s monumental’: FDA approves 1st OTC naloxone nasal spray
The approval follows an independent panel voting 19-0 in support of allowing for the product that reduces or reverses opioid overdoses to be given the OTC stamp. Northwell Health’s Sandeep Kapoor, MD, ...